Novartis' (NVS) LCZ696 drug for patients with ejection fraction heart failure, in which the organ's chambers are stiff but can still pump a reasonable amount of blood, performed well in a mid-stage trial. LCZ696 reduced levels of NT-proBNP, a protein that's linked to the condition. Larger studies are now needed to see whether this "biomarker" can lead to improved results in clinical practice.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Fri, 9:00AM)
at Zacks.com (Tue, 4:13PM)
at Investor's Business Daily (Mon, 4:49PM)
at Benzinga.com (Mon, 11:34AM)
at Investor's Business Daily (Jan 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs